Ypsomed Holding AG | Cash Flow

Fiscal year is April-March. All values CHF Thousands.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
13,608.00
19,395.00
35,812.00
46,247.00
52,060.00
60,136
Depreciation, Depletion & Amortization
24,530.00
26,076.00
27,117.00
30,689.00
34,469.00
44,888
Other Funds
256.00
6,971.00
7,550.00
2,935.00
2,740.00
44,690
Funds from Operations
37,882.00
52,442.00
70,479.00
79,871.00
83,789.00
60,334
Changes in Working Capital
3,324.00
11,061.00
6,208.00
4,805.00
30,520.00
475
Net Operating Cash Flow
41,206.00
41,381.00
76,687.00
75,066.00
53,269.00
59,859
Capital Expenditures
30,637.00
30,494.00
36,199.00
38,162.00
67,085.00
Sale of Fixed Assets & Businesses
561.00
5,218.00
222.00
110.00
1,255.00
Purchase/Sale of Investments
14.00
956.00
-
-
10.00
Net Investing Cash Flow
30,062.00
26,232.00
35,977.00
38,052.00
65,820.00
Cash Dividends Paid - Total
2,523.00
3,784.00
7,576.00
12,613.00
16,406.00
Issuance/Reduction of Debt, Net
2,000.00
11,500.00
22,001.00
12,000.00
22,001.00
Net Financing Cash Flow
4,523.00
14,167.00
31,662.00
23,231.00
4,595.00
Net Change in Cash
6,551.00
79.00
9,264.00
13,377.00
6,772.00
Free Cash Flow
22,676.00
24,169.00
51,533.00
47,584.00
2,241.00
Change in Capital Stock
-
1,117.00
2,085.00
1,382.00
1,000.00
Exchange Rate Effect
70.00
903.00
216.00
406.00
1,184.00

About Ypsomed Holding

View Profile
Address
Brunnmattstrasse 6
Burgdorf Bern (Berne) 3401
Switzerland
Employees -
Website http://www.ypsomed.com
Updated 07/08/2019
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. Its products include DiaExpert, BGMS, OmniPod, YpsoPump & Orbit, Pen needles, Injection systems, and Contract manufacturing. The company operates through the following business segments: Ypsomed Diabetes Care, Ypsomed Delivery Systems.